Analysts’ Weekly Ratings Changes for PhaseBio Pharmaceuticals (PHAS)

A number of research firms have changed their ratings and price targets for PhaseBio Pharmaceuticals (NASDAQ: PHAS):

  • 5/23/2019 – PhaseBio Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company’s product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States. “
  • 5/14/2019 – PhaseBio Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company’s product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States. “
  • 5/8/2019 – PhaseBio Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company’s product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States. “
  • 5/2/2019 – PhaseBio Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company’s product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States. “
  • 4/26/2019 – PhaseBio Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company’s product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States. “
  • 4/10/2019 – PhaseBio Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company’s product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States. “

Shares of PhaseBio Pharmaceuticals stock traded down $0.71 during trading on Thursday, hitting $9.87. 115,182 shares of the company’s stock traded hands, compared to its average volume of 338,146. The company has a debt-to-equity ratio of 0.19, a current ratio of 14.24 and a quick ratio of 14.24. PhaseBio Pharmaceuticals Inc has a 1 year low of $2.55 and a 1 year high of $16.65. The stock has a market capitalization of $260.66 million and a PE ratio of -2.20.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.14. The business had revenue of $0.65 million for the quarter, compared to analysts’ expectations of $0.12 million. As a group, sell-side analysts expect that PhaseBio Pharmaceuticals Inc will post -1.47 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in PHAS. BlackRock Inc. purchased a new stake in shares of PhaseBio Pharmaceuticals during the fourth quarter valued at $79,000. Tibra Equities Europe Ltd purchased a new stake in shares of PhaseBio Pharmaceuticals during the first quarter valued at $217,000. United Services Automobile Association purchased a new stake in shares of PhaseBio Pharmaceuticals during the fourth quarter valued at $286,000. Citigroup Inc. purchased a new stake in shares of PhaseBio Pharmaceuticals during the fourth quarter valued at $351,000. Finally, Millennium Management LLC purchased a new stake in shares of PhaseBio Pharmaceuticals during the fourth quarter valued at $411,000. 28.22% of the stock is currently owned by institutional investors.

PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.

Featured Article: Why is the LIBOR significant?

Receive News & Ratings for PhaseBio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.